Literature DB >> 6113614

Studies of prostaglandins and sulphasalazine in ulcerative colitis.

S R Gould, A R Brash, M E Conolly, J E Lennard-Jones.   

Abstract

Specific evidence is presented of the release of prostaglandins from the colon in active ulcerative colitis. An increase in the levels of bioassayed prostaglandin-like activity in the stools and colo-rectal venous plasma from patients with active ulcerative colitis is described. Radioimmunoassay confirms the presence of prostaglandin E and prostaglandin F in the stools in colitis. Increased urinary levels of prostaglandin F metabolite occur in patients with active colitis and return to normal as the disease becomes quiescent. Sulphasalazine and its faecal metabolite, 5-aminosalicylic acid, were shown by an indirect method (reduction of the tone of the isolated rat fundus strip) to inhibit prostaglandin biosynthesis in vitro. In contrast, sulphasalazine was without effect on the urinary excretion of prostaglandin F metabolite in 7 healthy subjects. In 2 patients with colitis withdrawal of sulphasalazine was associated with increasing levels of stool prostaglandin-like activity and urinary prostaglandin F metabolite excretion. Indomethacin, given to 3 patients with chronically active ulcerative colitis, unresponsive to standard medical treatment, was associated with a decreased urinary excretion of prostaglandin F metabolite but was without clinical benefit. The possible mode of action of sulphasalazine as a prostaglandin inhibitor in colitis is discussed along with the potential use of other prostaglandin inhibitors.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6113614     DOI: 10.1016/0161-4630(81)90088-4

Source DB:  PubMed          Journal:  Prostaglandins Med        ISSN: 0161-4630


  26 in total

Review 1.  Inflammatory intermediaries in inflammatory bowel disease.

Authors:  K Lauritsen; L S Laursen; K Bukhave; J Rask-Madsen
Journal:  Int J Colorectal Dis       Date:  1989       Impact factor: 2.571

Review 2.  Prostaglandins and cancer.

Authors:  D Wang; R N Dubois
Journal:  Gut       Date:  2005-08-23       Impact factor: 23.059

3.  Chemotactic activity in inflammatory bowel disease. Role of leukotriene B4.

Authors:  E A Lobos; P Sharon; W F Stenson
Journal:  Dig Dis Sci       Date:  1987-12       Impact factor: 3.199

4.  Inflammatory bowel disease in pregnancy.

Authors:  Dawn B Beaulieu; Sunanda Kane
Journal:  World J Gastroenterol       Date:  2011-06-14       Impact factor: 5.742

Review 5.  Prostaglandins and ulcerative colitis.

Authors:  D S Rampton; C J Hawkey
Journal:  Gut       Date:  1984-12       Impact factor: 23.059

6.  Inter-relationships between inflammatory mediators released from colonic mucosa in ulcerative colitis and their effects on colonic secretion.

Authors:  T D Wardle; L Hall; L A Turnberg
Journal:  Gut       Date:  1993-04       Impact factor: 23.059

7.  Ulcerative colitis: effect of sulphasalazine, its metabolites and indomethacin on the ability of human colonic mucosa to metabolize prostaglandins in vitro.

Authors:  K Hillier; P J Mason; S Pacheco; C L Smith
Journal:  Br J Pharmacol       Date:  1982-05       Impact factor: 8.739

8.  Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils.

Authors:  W F Stenson; E Lobos
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

Review 9.  The role of COX-2 in intestinal inflammation and colorectal cancer.

Authors:  D Wang; R N Dubois
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

10.  Effects of sulphasalazine and disodium azodisalicylate on colonic PGE2 concentrations determined by equilibrium in vivo dialysis of faeces in patients with ulcerative colitis and healthy controls.

Authors:  K Lauritsen; J Hansen; P Bytzer; K Bukhave; J Rask-Madsen
Journal:  Gut       Date:  1984-11       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.